Name Olmesartan Medoxomil
Classes Cardiovascular Agent
Antihypertensive
Angiotensin Receptor Blocker (ARB)
Diseases Cardiovascular Disease
Hypertension (High Blood Pressure)

Olmesartan Medoxomil

Olmesartan Medoxomil belongs to a class of drugs called Angiotensin II receptor blockers or ARBs. It prevents Angiotensin II from binding to Angiotensin receptor 1 and hence antagonizing it's effects.

The drug Olmesartan Medoxomil is used to treat hypertension. It can be taken alone or with other antihypertensive medications.

  • Olmesartan Medoxomil is available as tablets.

Adult dosage:

  • Olmesartan Medoxomil 10 mg once daily is the recommended beginning dose. The dose of Olmesartan Medoxomil may be increased to 20 mg once daily in people whose blood pressure is not properly managed at this dose. If further blood pressure control is needed, the dose of Olmesartan Medoxomil can be increased to a maximum of 40 mg per day, or hydrochlorothiazide therapy can be added.
  • Due to limited experience with larger dosages in this patient group, the maximum dose in patients with mild to moderate renal impairment (creatinine clearance of 20–60 mL/min) is 20 mg Olmesartan Medoxomil once day. Because there is relatively limited experience in this patient group, the use of Olmesartan Medoxomil in patients with severe renal impairment (creatinine clearance 20 mL/min) is not suggested.

Pediatric Dosage:

  • In children aged 6 to less than 18 years, a starting dose of 10 mg Olmesartan Medoxomil once daily is recommended. The dose of Olmesartan Medoxomil may be increased to 20 mg once daily in children whose blood pressure is not well managed at this dose.

Common side effects associated with Olmesartan Medoxomil are as follows-

  • Headache
  • Dizziness
  • Hyperlipidemia
  • Hyperglycemia
  • Bronchitis
  • Pharyngitis
  • Abdominal pain
  • Nausea
  • Changes in renal function may be expected in susceptible patients treated with Olmesartan Medoxomil as a result of suppressing the renin-angiotensin-aldosterone system.
  • Treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been linked to oliguria and/or progressive azotemia, as well as (rarely) acute renal failure and/or death in patients whose renal function may be dependent on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure). Patients receiving Olmesartan Medoxomil could expect similar results.

Contraindication

  • Olmesartan Medoxomil is contraindicated in patients who are hypersensitive to Olmesartan Medoxomil or other ARBs, such as-
  • Olmesartan Medoxomil should not be co-administered with the following drug in patients with diabetes and renal impairment-

Olmesartan Medoxomil is contraindicated in the following health conditions-